Update: Newborn Screening for Endocrinopathies

Endocrinology and Metabolism Clinics of North America

Volumn 38, Issue 4, 2009, Pages 827-837

  Pass, Kenneth A ^a   Neto, Eurico Carmago ^b  

^a WADSWORTH CENTER   (United States)

^b Centro de Triagem Neonatal   (Brazil)

Author keywords

Congenital adrenal hyperplasia; Congenital hypothyroidism; Dried blood specimen; Newborn screening

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID; GONADORELIN AGONIST; GROWTH HORMONE; LEVOTHYROXINE; METFORMIN; MINERALOCORTICOID;

CLINICAL PROTOCOL; CONGENITAL ADRENAL HYPERPLASIA; CONGENITAL HYPOTHYROIDISM; CONSENSUS DEVELOPMENT; COST BENEFIT ANALYSIS; CUSHING SYNDROME; ENDOCRINE DISEASE; FALSE POSITIVE RESULT; GENE MUTATION; GLAUCOMA; GROWTH RETARDATION; HEALTH CARE COST; HIRSUTISM; HUMAN; HYPERANDROGENISM; LABORATORY TEST; LONG TERM CARE; MEDICAL TECHNOLOGY; MENSTRUATION DISORDER; MUTATIONAL ANALYSIS; NEWBORN; NEWBORN SCREENING; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECOMMENDED DRUG DOSE; REVIEW; UROGENITAL TRACT MALFORMATION; UROLOGIC SURGERY;

ADRENAL HYPERPLASIA, CONGENITAL; CONGENITAL HYPOTHYROIDISM; ENDOCRINE SYSTEM DISEASES; FALSE POSITIVE REACTIONS; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; TREATMENT OUTCOME;

EID: 70449788009     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2009.08.005     Document Type: Review

References (73)

1. Watson M., Mann M., Lloyd-Puryear M., et al. Newborn screening: toward a uniform screening panel and system-executive summary. Pediatrics 117 5 (2006) S296-S307
2. Osotimehin M., Black E., and Hoffenbert R. Thyroglobulin concentration in neonatal blood: a possible test for neonatal hypothyroidism. Br Med J 2 (1978) 1467-1468
3. Gruneiro-Papendieck L., Prieto L., Chiese A., et al. Usefulness of thyroxine and free thyroxine filter paper measurements in neonatal screening for paper measurements in neonatal screening for congenital hypothyroidism of preterm babies. J Med Screen 7 (2000) 78-81
4. Fisher D., Dussault J., Foley T., et al. Screening for congenital hypothyroidism: results of screening 1 million North American infants. J Pediatr 94 5 (1979) 700-705
5. Djemli A., Van Vliet G., and Delvin E. Congenital hypothyroidism: from Paracelsus to molecular diagnosis. Clin Biochem 39 (2006) 511-518
6. Bellisario R., Colinas R., and Pass K. Simultaneous measurement of thyroxine and thyrotropin from newborn dried blood-spot specimens using a multiplexed fluorescent microsphere immunoassay. Clin Chem 46 9 (2000) 1422-1424
7. Mitchell M., and Hermos R. Measurement of thyroglobulin in newborn screening specimens from normal and hypothyroid infants. Clin Endocrinol 42 (1995) 523-527
8. Jones J., Mackenzie J., Croft G., et al. Improvement in screening performance and diagnosis of congenital hypothyroidism in Scotland 1979-2003. Arch Dis Child 91 (2006) 680-685
9. Howell R. The high price of false positives. Mol Genet Metab 87 (2006) 180-183
10. Kwon C., and Farrell P. The magnitude and challenge of false-positive newborn screening test results. Arch Pediatr Adolesc Med 154 (2000) 714-718
11. Polizzotti N., Carta A., Gelsomina R., et al. Longitudinal study of thyroid function in children with mild hyperthyrotropinemia at neonatal screening for congenital hypothyroidism. J Clin Endocrinol Metab 93 (2008) 2679-2685
12. Kohler B., Schnabel D., Biebermann H., et al. Transient congenital hypothyroidism and hyperthyrotropinemina: normal thyroid function and physical development at the ages of 6-14 years. J Clin Endocrinol Metab 81 4 (1996) 1563-1567
13. Pass K. How reliable is newborn screening for congenital adrenal hyperplasia?. Nat Clin Pract Endocrinol Metab 2 (2006) 74-75
14. LaFranchi S., Hanna C., Krainz P., et al. Screening for congenital hypothyroidism with specimen collection at two time periods: results of the Northwest Regional Screening Program. Pediatrics 76 (1985) 734-740
15. Harris K., and Pass K. Increase in congenital hypothyroidism in New York State and in the United States. Mol Genet Metab 91 (2007) 268-277
16. Harris K, Pass K, Vogt R, et al. Is congenital hypothyroidism increasing in the newborn population? 2008 Newborn Screening and Genetic Testing Symposium; November 4, 2008; San Antonio, TX.
17. Macchia P. Recent advances in understanding the molecular basis of primary congenital hypothyroidism. Mol Med Today 6 (2000) 36-42
18. Niu D., Lin C., Hwang B., et al. Contribution of genetic factors to neonatal transient hypothyroidism. Arch Dis Child Fetal Neonatal Ed 90 (2005) F69-F72
19. De Deken X., Wang D., Dumont J.E., et al. Characterization of ThOX proteins as components of the thyroid H(2)O(2)-generating system. Exp Cell Res 273 2 (2002) 187-196
20. Green N.S., and Pass K.A. Neonatal screening by DNA microarray: spots and chips. Nat Rev Genet 6 (2005) 147-151
21. Rose S., Brown R., Kaplowitz P., et al. Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics 117 (2006) 2290-2303
22. Kaiserman I., Siebner R., Kletter G., et al. A ten-year temporal analysis of primary congenital hypothyroidism in Israel. Early Hum Dev 26 3 (1991) 193-201
23. Bakker B., Kempers M., DeVijlder J., et al. Dynamics of the plasma concentrations of TSH, FT4 and T3 following thyroxine supplementation in congenital hypothyroidism. Clin Endocrinol (Oxf) 57 (2002) 529-537
24. Fisher D. Disorders of the thyroid in the newborn and infant. In: Sperling M.A. (Ed). Clinical pediatric and adolescent endocrinology (2002), Saunders, Philadelphia 164
25. Rapaport R., Rose S., and Freemark M. Hypothyroxinemia in the preterm infant: the benefits and risks of thyroxine treatment. J Pediatr 139 (2001) 182-188
26. Larson C., Hermos R., Delaney A., et al. Risk factors associated with delayed thyrotropin elevations in congenital hypothyroidism. J Pediatr 143 (2003) 587-591
27. Weber G., Vigone M., Rapa A., et al. Neonatal transient hypothyroidism: aetiological study. Arch Dis Child Fetal Neonatal Ed 79 (1998) F70-F72
28. Yang R., Zhu Z., Zhou X., et al. Treatment and follow-up of children with transient congenital hypothyroidism. J Zhejiang Univ Sci B 6 12 (2005) 1206-1209
29. Evans C., Jordan N., Owens G., et al. Potent thyrotrophin receptor-blocking antibodies: a cause of transient congenital hypothyroidism and delayed thyroid development. Eur J Endocrinol 150 (2004) 265-268
30. Ordookhani A., Mirmiran P., Walfish P., et al. Transient neonatal hypothyroidism is associated with elevated serum anti-thyroglobulin antibody levels in newborns and their mothers. J Pediatr 3 (2007) 315-317
31. Calaciura F., Motta R., Miscio G., et al. Subclinical hypothyroidism in early childhood: a frequent outcome of transient neonatal hyperthyrotropinemia. J Clin Endocrinol Metab 87 7 (2002) 3209-3214
32. Bongers-Schokking J., Koot H., Wiersma D., et al. Influence of timing and dose of thyroid hormone replacement on development in infants with congenital hypothyroidism. J Pediatr 136 (2000) 292-297
33. Zamproni I., Grasberger H., Cortinovis F., et al. Biallelic inactivation of the dual oxidase maturation factor 2 (DUOXA2) gene as a novel cause of congenital hypothyroidism. J Clin Endocrinol Metab 93 (2008) 605-610
34. Maruo Y., Takahashi H., Soeda I., et al. Transient congenital hypothyroidism caused by biallelic mutations of the dual oxidase 2 gene in Japanese patients detected by a neonatal screening program. J Clin Endocrinol Metab 93 (2008) 4261-4267
35. Jain V., Agarwal R., Deorari A., et al. Congenital hypothyroidism. Indian J Pediatr 75 (2008) 363-367
36. Salerno M., Oliviero U., Lettiero T., et al. Long-term cardiovascular effects of levothyroxine therapy in young adults with congenital hypothyroidism. J Clin Endocrinol Metab 93 7 (2008) 2486-2491
37. Rovet J. Congenital hypothyroidism: an analysis of persisting deficits and associated factors. Child Neuropsychol 8 3 (2002) 150-162
38. Heyerdahl S., and Oerbeck B. Congenital hypothyroidism: developmental outcome in relation to levothyroxine treatment variables. Thyroid 13 (2003) 1029-1038
39. Morin A., Guimarey L., and Apezteguia M. Linear growth in children with congenital hypothyroidism detected by neonatal screen and treated early: a longitudinal study. J Pediatr Endocrinol Metab 15 (2002) 973-977
40. Oerbeck B., Sundet K., Kase B., et al. Congenital hypothyroidism: influence of disease severity and L-thyroxine treatment on intellectual, motor, and school-associated outcomes in young adults. Pediatrics 112 (2003) 923-930
41. Gruters A., Jenner A., and Krude H. Long-term consequences of congenital hypothyroidism in the era of screening programmes. Best Pract Res Clin Endocrinol Metab 16 (2002) 369-382
42. Oken E., Braverman L., Platek D., et al. Neonatal thyroxine, maternal thyroid function, and child cognition. J Clin Endocrinol Metab 93 (2008) 2648-2653
43. Bongers-Schokking J. Pre- and postnatal brain development in neonates with congenital hypothyroidism. J Pediatr Endocrinol Metab 14 Suppl 6 (2001) 1463-1468
44. Kreisner E., Schermann L., Camargo-Neto E., et al. Predictors of intellectual outcome in a cohort of Brazilian children with congenital hypothyroidism. Clin Endocrinol (Oxf) 60 (2004) 250-255
45. Cassio A., Cacciari E., Cicognani A., et al. Treatment for congenital hypothyroidism: thyroxine alone or thyroxine plus triiodothyronine?. Pediatrics 111 (2003) 1055-1060
46. Kurinczuk J., Bower C., Lewis B., et al. Congenital hypothyroidism in Western Australia 1981-1998. J Paediatr Child Health 38 (2002) 187-191
47. Veer L., Kempers M., Last B., et al. Quality of life, developmental milestones, and self-esteem of young adults with congenital hypothyroidism diagnosed by neonatal screening. J Clin Endocrinol Metab 93 (2008) 2654-2661
48. Merke D.P., and Bornstein S.R. Congenital adrenal hyperplasia. Lancet 365 (2005) 125-136
49. Krone N., Dhir V., Ivison H., et al. Congenital adrenal hyperplasia and P450 oxidoreductase deficiency. Clin Endocrinol 66 (2000) 162-172
50. Speiser P., and White P. Congenital adrenal hyperplasia. N Engl J Med 349 (2003) 776-788
51. Torresani T., Grüters A., Scherz R., et al. Improving the efficacy of newborn screening for congenital adrenal hyperplasia by adjusting the cut-off level of 17β-hydroxyprogesterone to gestational age. Screening 3 (1994) 77-84
52. Riepe F., and Sippell W. Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Rev Endocr Metab Disord 8 (2007) 349-363
53. Pang S., Hotchkiss J., Drash A.L., et al. Microfilter paper method for 17β-hydroxyprogesterone radioimmunoassay: its application for rapid screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 45 (1977) 1003-1008
54. Dressendorfer R., Strasburger C., Bidlingmaier F., et al. Development of a highly sensitive nonisotopic immunoassay for the determination of salivary 17-hydroxyprogesterone: reference ranges throughout childhood and adolescence. Pediatr Res 44 (1998) 650-655
55. Janzen N., Peter M., Sander S., et al. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 92 (2007) 2581-2589
56. Matern D., Tortorelli S., Oglesbee D., et al. Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004-2007). J Inherit Metab Dis 30 (2007) 585-592
57. Minutti C., Lacey J., Magera M., et al. Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 89 (2004) 3687-3693
58. Lee J., Moon Y., Lee M., et al. Corrected 17-alpha-hydroxyprogesterone values adjusted by a scoring system for screening congenital adrenal hyperplasia in premature infants. Ann Clin Lab Sci 38 (2008) 235-240
59. Allen D., Hoffman G., Fitzpatrick P., et al. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr 130 (1994) 128-133
60. Olgemöller B., Roscher A., Liebl B., et al. Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value. J Clin Endocrinol Metab 88 (2003) 5790-5794
61. Gruneiro-Papendieck L., Prieto L., Chiesa A., et al. Neonatal screening program for congenital adrenal hyperplasia: adjustments to the recall protocol. Horm Res 55 (2001) 271-277
62. Dhondt J.L. Neonatal screening: from the 'Guthrie age' to the 'genetic age'. J Inherit Metab Dis 30 (2007) 418-422
63. Wudy S.A., Hartmann M., and Svoboda M. Determination of 17-hydroxyprogesterone in plasma by stable isotope dilution/benchtop liquid chromatography-tandem mass spectrometry. Horm Res 53 (2000) 68-71
64. Nordenstrom A., Wedell A., Hagenfeldt L., et al. Neonatal screening for congenital adrenal hyperplasia: 17-hydroxyprogesterone levels and CYP21 genotypes in preterm infants. Pediatrics 108 (2001) 68-74
65. Wudy S., Wachter U., Homoki J., et al. 17β-Hydroxyprogesterone, 4-androstenedione, and testosterone profiled by routine stable isotope dilution/gas chromatography-mass spectrometry in plasma of children. Pediatr Res 38 (1995) 76-80
66. Peter M., Viemann M., Partsch C., et al. Congenital adrenal hypoplasia: clinical spectrum: experience with hormonal diagnosis, and report on new point mutations of the DAX-1 gene. J Clin Endocrinol Metab 83 (1998) 2666-2674
67. Torresani T., and Biason-Lauber A. Congenital adrenal hyperplasia: diagnostic advances. J Inherit Metab Dis 30 (2007) 563-575
68. Quintos J.B., Vogiatzi M.G., Harbison M.D., et al. Growth hormone therapy alone or in combination with gonadotropin releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 86 (2001) 1511-1517
69. Arslanian S.A., Lewy V., Danadian K., et al. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 87 (2002) 1555-1559
70. Marca A., Morgante G., Paglia T., et al. Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. Fertil Steril 72 (1999) 985-989
71. Bornstein S., Webster E., Torpy D., et al. Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation. Endocrinology 139 (1998) 1546-1555
72. Webster E., Lewis D., Torpy D., et al. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137 (1996) 5747-5750
73. Brosco J., Seider M., and Dunn A. Universal newborn screening and adverse medical outcomes: a historical note. Ment Retard Dev Disabil Res Rev 12 (2006) 262-269